Path Corporation
Stock Price Chart
2026/08/13 UpdatedPrice Trend
2026/08/13 UpdatedPrice & Trading Details
2026/08/13 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/09 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,992M | ¥2,320M | ¥2,254M | ¥2,370M |
| Gross Profit | ¥972M | ¥1,101M | ¥1,174M | ¥1,157M |
| Operating Income | -¥220M | -¥172M | -¥208M | -¥774M |
| Pretax Income | -¥252M | -¥161M | -¥266M | -¥1,271M |
| Net Income | -¥256M | -¥176M | -¥277M | -¥1,277M |
| EPS | -¥5.46 | -¥3.31 | -¥4.36 | - |
| Operating Margin | -11.06% | -7.43% | -9.25% | -32.66% |
| Balance Sheet | ||||
| Total Assets | ¥1,450M | ¥1,678M | ¥3,252M | ¥2,527M |
| Total Equity | ¥1,100M | ¥1,201M | ¥2,475M | ¥1,906M |
| Total Liabilities | ¥351M | ¥477M | ¥777M | ¥621M |
| Cash | ¥173M | ¥297M | ¥155M | ¥357M |
| Interest-bearing Debt | ¥0M | ¥0M | ¥293M | ¥250M |
| Equity Ratio | 75.83% | 71.57% | 76.10% | 75.42% |
| D/E Ratio | 0.00 | 0.00 | 0.12 | 0.13 |
| Cash Flow | ||||
| Operating CF | -¥352M | -¥77M | -¥539M | -¥435M |
| Investing CF | -¥114M | -¥87M | -¥525M | -¥319M |
| Financing CF | ¥281M | ¥288M | ¥914M | ¥957M |
| Free CF | -¥468M | -¥159M | -¥1,061M | -¥493M |
| Efficiency | ||||
| ROE | -23.29% | -14.65% | -11.18% | -66.99% |
| ROA | -17.66% | -10.48% | -8.51% | -50.52% |
Latest IR Information
-
Q1 FY2027 Financial Summary (Consolidated) [Japanese GAAP]
For the first quarter of FY2027, consolidated net sales were 587,612 thousand yen, operating loss 130,261 thousand yen, ordinary loss 106,092 thousand yen, and net loss attributable to owners of the parent 107,018 thousand yen. Compared with the same period...
Read more -
Notice Regarding Recording of Revenue from Non-Operating Income (Crypto Asset Valuation Gain)
Recorded a crypto asset valuation gain of 56,862 thousand yen as non-operating income. Please refer to the financial results document for impact on performance.
Read more -
Unknown
Reports on other affiliated companies for the fiscal year ending March 2026. Sustin's voting rights ownership ratio is 36.9%, with no concurrent officer positions, ensuring independence. Transaction details include issuance and exercise of share subscription rights and fund borrowing.
Read more -
Joint Research Agreement with Subsidiary and Tokyo Medical University | July 21, 2026
RMDC has concluded a joint research agreement with Tokyo Medical University to develop stem cell culture technology for regenerative medicine, aiming to create new culture devices. The research period is from July 2026 to June 2027, collaborating with the world-renowned...
Read more -
Notice Regarding Financial Results of Unlisted Parent Company, etc.
Read more
Latest News (5 items)
Company Information
About
Path Corporation primarily engages in the e-commerce business in Japan. The company offers cosmetics, beauty and wellness, and regenerative medicine products. It is also involved in the research, development, and sale of microalgae and extracts; manufacture and sale of human-derived cosmetic raw materials; and biomass power generation business. The company sells its products to distributors, retailers, and consumers. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
